Background Upadacitinib is an oral, selective Janus kinase inhibitor. Aim To assess the
efficacy and safety of upadacitinib in patients with moderate‐to‐severe ulcerative colitis …

Background Upadacitinib (UPA), a selective and reversible Janus kinase inhibitor, has been
shown to be safe and effective when administered at a dose of 45 mg once daily (QD) as 8 …

Incorporation coefficients k* of intravenously injected [3 H] arachidonic acid from blood into
brain reflect the release from phospholipids of arachidonic acid by receptor-initiated …

The aim of this study was to compare the ease and accuracy of measuring the surface area
of a severe burn through the use of a mobile software application (BurnMed) to the …

Objective To assess the immunogenicity of pneumococcal 13-valent conjugate vaccination
(PCV-13) in patients with rheumatoid arthritis receiving upadacitinib and background …

Abstract Fluoxetine, a selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitor, is
used widely to treat depression and related disorders. By inhibiting presynaptic 5-HT …

Serotonergic 5-HT2A/2C receptors can be coupled to phospholipase A2 (PLA2) activation to
release the second messenger, arachidonic acid (AA), from membrane phospholipids. We …

Methods: Patients who did not achieve clinical response (Adapted Mayo score decrease≥ 2
points and≥ 30% from baseline, plus≥ 1 point decrease in rectal bleeding score [RBS] or …

In vitro studies have shown that 5-HT2 receptors can be coupled via G-proteins to
phospholipase A2 (PLA2) activation, releasing arachidonic acid from phospholipids. To …

Background Upadacitinib (UPA), an oral selective and reversible JAK inhibitor,
demonstrated significantly greater efficacy compared to placebo (PBO) as treatment for …